00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
19:22 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Spring Bank details peak HBV DNA and HBV RNA reductions for 100 mg dose of inarigivir

Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) reported data from 20 patients in the third cohort of Part A of Phase II ACHIEVE trial to treat chronic HBV infection showing that 100 mg inarigivir soproxil led to...
14:10 , Apr 3, 2018 |  BC Innovations  |  Targets & Mechanisms

Sensor sensibility

Zhijian “James” Chen’s discovery of the DNA sensor cGAS revealed the missing link between cytosolic DNA and innate immune activation, paving the way for immunotherapies targeting the cGAS-STING pathway. The lowest-hanging fruit has been in...
02:11 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Pathways emerging from ASH

A survey of the emerging molecular targets at this year’s American Society of Hematology conference indicates that while harnessing the immune system to treat cancer remains a dominant interest, processes for tuning protein levels --...
18:52 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

Spring Bank reports Phase II data for HBV candidate

Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) reported data from 20 treatment-naive patients with chronic HBV infection without cirrhosis in the first cohort of the Phase II ACHIEVE trial showing that once-daily 25 mg inarigivir soproxil (formerly...
20:19 , Sep 8, 2017 |  BC Week In Review  |  Company News

Merck acquires cancer play Rigontec

Merck & Co. Inc. (NYSE:MRK) is acquiring immuno-oncology company Rigontec GmbH (Munich, Germany). Rigontec will receive €115 million ($136.8 million) in cash up front and is eligible for up to €349 million ($415.2 million) in...
18:33 , Sep 8, 2017 |  BioCentury  |  Finance

Rig-ging an exit

Wellington Partners’ quick exit from Rigontec GmbH will not only be one of the firm’s best returns from its current fund, but could bolster its fund-raising efforts for a third life sciences fund. On Sept....
23:22 , Sep 6, 2017 |  BC Extra  |  Company News

Merck acquires cancer play Rigontec

Merck & Co. Inc. (NYSE:MRK) is acquiring immuno-oncology company Rigontec GmbH (Munich, Germany). Rigontec will receive €115 million ($136.8 million) in cash up front and is eligible for up to €349 million ($415.2 million) in...
00:42 , Aug 12, 2017 |  BioCentury  |  Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...
18:45 , Jul 21, 2017 |  BC Week In Review  |  Company News

Spring Bank and Gilead combo trial to treat chronic HBV

Gilead Sciences Inc. (NASDAQ:GILD) will fund and conduct a Phase II evaluating its HBV drug Vemlidy tenofovir alafenamide fumarate plus SB 9200 from Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) in patients with chronic HBV infection. Spring...